VoxNeuro, a company that develops EEG-based brain performance software, announced the completion of its second financing round with nearly $3.4 million raised.
The funding round was led by the company’s largest shareholder, in addition to its strategic investor g.tec, a brain-computer interface and neurotechnology company that serves as VoxNeuro's strategic supplier of EEG hardware. The financing will be used to execute commercial expansion plans to scale clinical installations across the U.S. to meet the growing demand for cognitive assessments, promote brain health equity, and continue to perform software enhancements through research and development.
The closing follows a quarter of significant milestones which include: securing ten new client agreements; partnering with Boston University to develop validated diagnostic tools for targeted application in Concussion and Alzheimer’s patients; exhibiting at the 75th American Academy of Neurology (AAN) Annual Meeting in Boston and the Collision tech conference in Toronto. Additionally, VoxNeuro delivered a keynote presentation on the value of adding objective data for all players via their language-agnostic medical technology at the Annual Professional Hockey Athletic Trainers Society and Society Of Professional Hockey Equipment Managers (PHATS/SPHEM) Conference in Phoenix, AZ with a target audience of medical teams and trainers from the National Hockey League (NHL), American Hockey League (AHL) and Canadian Hockey League (CHL).
Further in its robust pipeline, VoxNeuro is developing a machine-learning (ML) enhancement to its current clinical tool. The new machine learning algorithm boasts advanced features that promote increased precision, specificity and a more holistic view of patients’ cognitive health. With an established client success team along with an extensive sales and marketing strategy in place, the Company continues to transform the brain health landscape with its objective cognitive health assessments.
